Adverse Events of Monoclonal Antibodies Used for Cancer Therapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Guan, Mei ^a   Zhou, Yan Ping ^a   Sun, Jin Lu ^a   Chen, Shu Chang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALCLOMETASONE; CLINDAMYCIN; DIPHENHYDRAMINE; DOXYCYCLINE; FLUOCINONIDE; ISOTRETINOIN; MINOCYCLINE; MONOCLONAL ANTIBODY; PARACETAMOL; CANCER ANTIBODY; RITUXIMAB;

ABDOMINAL PAIN; ACNE; ADVERSE DRUG REACTION; ANAPHYLAXIS; ANOREXIA; ARTERIAL THROMBOEMBOLISM; BLEEDING; CANCER IMMUNOTHERAPY; CLINICAL TRIAL (TOPIC); COLITIS; CONFUSION; CONGESTIVE HEART FAILURE; CYTOPENIA; DESENSITIZATION; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DISORIENTATION; DRUG HYPERSENSITIVITY; DYSPHONIA; ENTEROCOLITIS; FATIGUE; HEMIPARESIS; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; LUNG DISEASE; MUCOSA INFLAMMATION; NEPHROTIC SYNDROME; PAPULOPUSTULAR ACNEIFORM ERUPTION; PARONYCHIA; PERIPHERAL NEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; REVIEW; RISK ASSESSMENT; SERUM SICKNESS; SPEECH DISORDER; STANDARD INFUSION REACTION; STOMATITIS; VENOUS THROMBOEMBOLISM; VOMITING; NEOPLASMS;

ANTIBODIES, NEOPLASM; HUMANS; NEOPLASMS; RITUXIMAB;

EID: 84929630527     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/428169     Document Type: Review

References (95)

1. A.Muraro, G. Roberts, and M.Worm, "Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology,"Allergy, vol. 69, pp. 1026-1045, 2014.
2. Zevalin, FDA: Full Prescribing Information. Adverse Reactions, 2013, http://www.accessdata.fda.gov/drugsatfda docs/label/ 2009/125019s0156.pdf.
3. Bexxar, FDA: Full prescribing information. Adverse reactions, 2013, http://www.accessdata.fda.gov/drugsatfda docs/label/ 2012/125011s102lbl.pdf.
4. E. R. Gomes and P. Demoly, "Epidemiology of hypersensitivity drug reactions," Current Opinion in Allergy and Clinical Immunology, vol. 5, no. 4, pp. 309-316, 2005.
5. E. Kimby, "Tolerability and safety of rituximab (MabThera),"Cancer Treatment Reviews, vol. 31, no. 6, pp. 456-473, 2005.
6. M. Castells, "Rapid desensitization for hypersensitivity reactions to medications," Immunology and Allergy Clinics of North America, vol. 29, no. 3, pp. 585-606, 2009.
7. C. H. Chung, B. Mirakhur, E. Chan et al., "Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3- galactose," The New England Journal of Medicine, vol. 358, no. 11, pp. 1109-1117, 2008.
8. R. Jankowitz, J. Joyce, and S. A. Jacobs, "Anaphylaxis after administration of ibritumomab tiuxetan for follicular non- Hodgkin lymphoma," Clinical Nuclear Medicine, vol. 33, no. 2, pp. 94-96, 2008.
9. T. Rispens, N. I. L. Derksen, S. P. Commins, T. A. Platts-Mills, and R. C. Aalberse, "IgE Pro- ductiontoa -Gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B," PLoS ONE, vol. 8, no. 2, Article ID e55566, 2013.
10. E. A. Berg, T. A. Platts-Mills, and S. P. Commins, "Drug allergens and food - the cetuximab and galactose-α-1, 3-galactose story," Annals of Allergy, Asthma & Immunology, vol. 112, no. 2, pp. 97-101, 2014.
11. C. H. Chung, B. Mirakhur, E. Chan et al., "Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3- galactose," The New England Journal of Medicine, vol. 358, no. 11, pp. 1109-1117, 2008.
12. P. McLaughlin, A. J. Grillo-López, B. K. Link et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program," Journal of Clinical Oncology, vol. 16, no. 8, pp. 2825-2833, 1998.
13. A. Sandhu, A. Harford, and P. Singh, "Is thymoglobulin or rituximab the cause of this serum sickness? A case report of serum sickness dilemma and literature review," Case Reports in Medicine, vol. 2012, Article ID 234515, 7 pages, 2012.
14. G. Le Guenno, M. Ruivard, L. Charra, and P. Philippe, "Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura," Internal Medicine Journal, vol. 41, no. 2, pp. 202-205, 2011.
15. M. J. Keating, I. Flinn, V. Jain et al., "Therapeutic role of alemtuzumab (Campath-1H) in patientswho have failed fludarabine: results of a large international study," Blood, vol. 99, no. 10, pp. 3554-3561, 2002.
16. A. Shablak and A. Conn, "A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment,"Targeted Oncology, vol. 9, no. 2, pp. 177-180, 2014.
17. D. Cunningham, Y. Humblet, S. Siena et al., "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer,"The New England Journal of Medicine, vol. 351, no. 4, pp. 337-345, 2004.
18. E. Van Cutsem, M. Peeters, S. Siena et al., "Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapyrefractory metastatic colorectal cancer," Journal of Clinical Oncology, vol. 25, no. 13, pp. 1658-1664, 2007.
19. T. J. Price, M. Peeters, T. W. Kim et al., "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study," The Lancet Oncology, vol. 15, no. 6, pp. 569-579, 2014.
20. D. Strumberg, B. Schultheis, M. E. Scheulen et al., "Phase II study of nimotuzumab, a humanized monoclonal antiepidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer," Investigational New Drugs, vol. 30, no. 3, pp. 1138-1143, 2012.
21. B. K. Reddy, V. Lokesh, M. S. Vidyasagar et al., "Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients," Oral Oncology, vol. 50, no. 5, pp. 498-505, 2014.
22. E. Tan-Chiu, G. Yothers, E. Romond et al., "Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31," Journal of Clinical Oncology, vol. 23, no. 31, pp. 7811-7819, 2005.
23. S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu, "Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis," The Journal of the American Medical Association, vol. 300, no. 19, pp. 2277-2285, 2008.
24. T.K.Choueiri, E. L. Mayer, Y. Je et al., "Congestive heart failure risk in patients with breast cancer treated with bevacizumab,"Journal of Clinical Oncology, vol. 29, no. 6, pp. 632-638, 2011.
25. P. Y. Zuo, X. L. Chen, and Y. W. Liu, "Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis," PLoS ONE, vol. 9, no. 7, Article ID e102484, 2014.
26. A. F. C. Okines, R. E. Langley, L. C. Thompson et al., "Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report," Annals of Oncology, vol. 24, no. 3, Article ID mds533, pp. 702-709, 2013.
27. S. M. Gressett and S. R. Shah, "Intricacies of bevacizumab - induced toxicities and their management," Annals of Pharmacotherapy, vol. 43, no. 3, pp. 490-501, 2009.
28. C. S. Fuchs, J. Tomasek, C. J. Yong et al., "Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial," The Lancet, vol. 383, no. 9911, pp. 31-39, 2014.
29. A. X. Zhu, R. S. Finn, M. Mulcahy et al., "A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer," Clinical Cancer Research, vol. 19, no. 23, pp. 6614-6623, 2013.
30. J. A. Garcia, G. R. Hudes, T. K. Choueiri et al., "A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy," Cancer, vol. 120, no. 11, pp. 1647-1655, 2014.
31. M. S. Ewer, M. T. Vooletich, J.-B. Durand et al., "Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment," Journal of Clinical Oncology, vol. 23, no. 31, pp. 7820-7826, 2005.
32. M. Procter, T. M. Suter, E. de Azambuja et al., "Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial," Journal of Clinical Oncology, vol. 28, no. 21, pp. 3422-3428, 2010.
33. X. L. Du, R. Xia, K. Burau, and C. C. Liu, "Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005," Medical Oncology, vol. 28, supplement 1, pp. S80-S90, 2011.
34. B. Vahid and A. Mehrotra, "Trastuzumab (Herceptin)- associated lung injury," Respirology, vol. 11, no. 5, pp. 655-658, 2006.
35. Herceptin (trastuzumab for injection), FDA approved package insert. US National Library of Medicine, 2010, http://www .dailymed.nlm.nih.gov/.
36. S. Verma, D. Miles, L. Gianni et al., "Trastuzumabemtansine for HER2-positive advanced breast cance," The New England Journal of Medicine, vol. 367, no. 19, pp. 1783-1791, 2012.
37. S. Girish, M. Gupta, B. Wang et al., "Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer,"Cancer Chemotherapy and Pharmacology, vol. 69, no. 5, pp. 1229-1240, 2012.
38. J. Corteś, P. Fumoleau, G. Bianchi et al., "Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer," Journal of Clinical Oncology, vol. 30, no. 14, pp. 1594-1600, 2012.
39. L. Gianni, T. Pienkowski, Y. H. Im et al., "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere) : a randomised multicentre, open-label, phase 2 trial," The Lancet Oncology, vol. 13, pp. 25-32, 2012.
40. J. Abraham and M. Stenger, "Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer," Journal of Community and Supportive Oncology, vol. 12, no. 3, pp. 84-86, 2014.
41. A. De Masson, P. Guitera, P. Brice et al., "Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous Tcell lymphomas," British Journal of Dermatology, vol. 170, no. 3, pp. 720-724, 2014.
42. T. Elter, L. Gercheva-Kyuchukova, H. Pylylpenko et al., "Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial," The Lancet Oncology, vol. 12, no. 13, pp. 1204-1213, 2011.
43. H. Lioté, F. Lioté, B. Séroussi et al., "Rituximab-induced lung disease: a systematic literature review," European Respiratory Journal, vol. 35, no. 3, pp. 681-687, 2010.
44. O. W. Press, J. M. Unger, L. M. Rimsza et al., "Phase III randomized intergroup trial ofCHOP plus rituximab compared withCHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: SWOG S0016," Journal of Clinical Oncology, vol. 31, no. 3, pp. 314-320, 2013.
45. Y. Ogawa, M. Ogura, T. Suzuki et al., "A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia,"International Journal of Hematology, vol. 98, no. 2, pp. 164-170, 2013.
46. W.G.Wierda, T. J. Kipps, J.Mayer et al., "Ofatumumabas singleagent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia," Journal of Clinical Oncology, vol. 28, no. 10, pp. 1749-1755, 2010.
47. F. A. Morschhauser, G. Cartron, C. Thieblemont et al., "Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase IIGAUGUIN study," Journal of Clinical Oncology, vol. 31, no. 23, pp. 2912-2919, 2013.
48. J. Radford, A. Davies, G. Cartron et al., "Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (B021000)," Blood, vol. 122, no. 7, pp. 1137-1143, 2013.
49. F. Morschhauser, J. Radford, A. Van Hoof et al., "90Yttriumibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial," Journal of Clinical Oncology, vol. 31, no. 16, pp. 1977-1983, 2013.
50. J. M. Vose, S. Carter, L. J. Burns et al., "Phase III randomized study of rituximab/ carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab /BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial," Journal of Clinical Oncology, vol. 31, pp. 1662-1668, 2013.
51. B. K. Link, P. Martin, M. S. Kaminski, S. J. Goldsmith, M. Coleman, and J. P. Leonard, "Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131- tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study," Journal of Clinical Oncology, vol. 28, no. 18, pp. 3035-3041, 2010.
52. M. A. Fanale, A. Forero-Torres, J. D. Rosenblatt et al., "A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies,"Clinical Cancer Research, vol. 18, no. 1, pp. 248-255, 2012.
53. A. Younes, A. K. Gopal, S. E. Smith et al., "Results of a pivotal phase II study of brentuximabvedotin for patients with relapsed or refractory Hodgkin's lymphoma," Journal of Clinical Oncology, vol. 30, no. 18, pp. 2183-2189, 2012.
54. T. Siddiqi, S. H. Thomas, and R. Chen, "Role of brentux-imabvedotin in the treatment of relapsed or refractoryHodgkin lymphoma," Pharmacogenomics and PersonalizedMedicine, vol. 7, pp. 79-85, 2014.
55. A. Younes, J. M. Connors, S. I. Park et al., "Brentuximabvedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, doseescalation study," The Lancet Oncology, vol. 14, pp. 1348-1356, 2013.
56. L. A. Fecher, S. S. Agarwala, F. Stephen Hodi, and J. S. Weber, "Ipilimumab and its toxicities: a multidisciplinary approach,"The Oncologist, vol. 18, no. 6, pp. 733-743, 2013.
57. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., "Improved survival with ipilimumab in patients with metastaticmelanoma,"TheNewEngland Journal ofMedicine, vol. 363, pp. 711-723, 2010.
58. M. M. Heiss, P.Murawa, P. Koralewski et al., "The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial," International Journal of Cancer, vol. 127, no. 9, pp. 2209-2221, 2010.
59. S. Adami, C. Libanati, S. Boonen et al., "Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial," Journal of Bone and Joint Surgery A, vol. 94, no. 23, pp. 2113-2119, 2012.
60. D. H. Henry, L. Costa, F. Goldwasser et al., "Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma,"Journal of Clinical Oncology, vol. 29, no. 9, pp. 1125-1132, 2011.
61. S. L. Topalian, M. Sznol, D. F. McDermott et al., "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab," Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020-1030, 2014.
62. R. Kurzrock, P. M. Voorhees, C. Casper et al., "A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or castleman disease," Clinical Cancer Research, vol. 19, no. 13, pp. 3659-3670, 2013.
63. M. C. Castells, N. M. Tennant, D. E. Sloane et al., "Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases," Journal ofAllergyandClinical Immunology, vol. 122, no. 3, pp. 574-580, 2008.
64. F. Torino, A. Barnabei, L. de Vecchis, R. Salvatori, and S. M. Corsello, "Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease," Oncologist, vol. 17, no. 4, pp. 525-535, 2012.
65. S. M. Corsello, A. Barnabei, P. Marchetti, L. De Vecchis, R. Salvatori, and F. Torino, "Endocrine side effects induced by immune checkpoint inhibitors," The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 4, pp. 1361-1375, 2013.
66. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer," New England Journal of Medicine, vol. 366, no. 26, pp. 2443-2454, 2012.
67. A. Ribas, F. S. Hodi, R. Kefford et al., "Efficacy and safety of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients (pts) with melanoma (MEL)," in Proceedings of the American Society of Clinical OncologyMeeting (ASCO '14), 2014, (Abstract LBA9000).
68. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," The New England Journal of Medicine, vol. 350, no. 23, pp. 2335-2342, 2004.
69. I. E. Krop, S. B. Kim, A. González-Martín et al., "TH3RESA study collaborators Trastuzumabemtansine versus treatment of physician's choice for pretreatedHER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial,"The Lancet Oncology, vol. 15, no. 7, pp. 689-699, 2014.
70. P. Madeddu, "Therapeutic angiogenesis and vasculogenesis for tissue regeneration," Experimental Physiology, vol. 90, no. 3, pp. 315-326, 2005.
71. E. S. Robinson, E.V.Khankin, T.K. Choueiri et al., "Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors," Hypertension, vol. 56, no. 6, pp. 1131-1136, 2010.
72. H. Izzedine, S. Ederhy, F. Goldwasser et al., "Management of hypertension in angiogenesis inhibitor-treated patients," Annals of Oncology, vol. 20, no. 5, pp. 807-815, 2009.
73. R. Dienstmann, I. Braña, J. Rodon, and J. Taberanero, "Toxicity as a biomarker of efficacy ofmolecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs," Oncologist, vol. 16, no. 12, pp. 1729-1740, 2011.
74. J. A. Garcia, G. R. Hudes, T. K. Choueiri et al., "A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy," Cancer, vol. 120, no. 11, pp. 1647-1655, 2014.
75. F. A. Scappaticci, J. R. Skillings, S. N. Holden et al., "Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab," Journal of the National Cancer Institute, vol. 99, pp. 1232-1239, 2007.
76. J.-Y. Pierga, T. Petit, T. Delozier et al., "Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an openlabel, single-arm phase 2 study," The Lancet Oncology, vol. 13, no. 4, pp. 375-384, 2012.
77. C. Criscitiello, O. Metzger-Filho, K. S. Saini et al., "Targeted therapies in breast cancer: are heart and vessels also being targeted?" Breast Cancer Research, vol. 14, no. 3, article 209, 2012.
78. E. Radzikowska, E. Szczepulska, M. Chabowski, and I. Bestry, "Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer," European Respiratory Journal, vol. 21, no. 3, pp. 552-555, 2003.
79. M. J. Pepels, K. A. Boomars, R. van Kimmenade, and P. S. Hupperets, "Life-threatening interstitial lung disease associated with trastuzumab: case report," Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 609-612, 2009.
80. H. Izzedine, C. Massard, J. P. Spano, F. Goldwasser, D. Khayat, and J. C. Soria, "VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management," European Journal of Cancer, vol. 46, no. 2, pp. 439-448, 2010.
81. V. Eremina, J. A. Jefferson, J. Kowalewska et al., "VEGF inhibition and renal thrombotic microangiopathy," The New England Journal ofMedicine, vol. 358, no. 11, pp. 1129-1136, 2008.
82. G. Bollée, N. Patey, G. Cazajous et al., "Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib,"Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 682-685, 2009.
83. J.-M. Halimi, M. Azizi, G. Bobrie et al., "Vascular and renal effects of anti-angiogenic therapy," Nephrologie et Therapeutique, vol. 4, no. 7, pp. 602-615, 2008.
84. R. Pirker, J. R. Pereira, J. von Pawel et al., "EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study," The Lancet Oncology, vol. 13, no. 1, pp. 33-42, 2012.
85. S. E. Borofsky, M. S. Levine, S. E. Rubesin, J. L. Tanyi, C. S. Chu, and A. S. Lev-Toaff, "Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients," Abdominal Imaging, vol. 38, no. 2, pp. 265-272, 2013.
86. T. Li and R. Perez-Soler, "Skin toxicities associated with epidermal growth factor receptor inhibitors," Targeted Oncology, vol. 4, no. 2, pp. 107-119, 2009.
87. T. Eames, B. Grabein, J. Kroth, and A. Wollenberg, "Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia," Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 8, pp. 958-960, 2010.
88. M. E. Lacouture, M. J. Anadkat, R.-J. Bensadoun et al., "Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities," Supportive Care in Cancer, vol. 19, no. 8, pp. 1079-1095, 2011.
89. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.," Journal of Clinical Oncology, vol. 21, no. 1, pp. 60-65, 2003.
90. C. D. Schweighofer and C.-M. Wendtner, "First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab," Onco Targets andTherapy, vol. 3, pp. 53-67, 2010.
91. W. Wang, L. R. Zhao, X. Q. Lin, and F. Feng, "Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer," World Journal of Gastroenterology, vol. 20, no. 21, pp. 6691-6697, 2014.
92. M. B. Atkins, R. R. Kudchadkar, M. Sznol et al., "Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma," in Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14), 2014, abstract no. 9001.
93. B. C. Creelan, "Update on immune checkpoint inhibitors in lung cancer," Cancer Control, vol. 21, no. 1, pp. 80-89, 2014.
94. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,"The New England Journal of Medicine, vol. 366, no. 26, pp. 2455-2465, 2012.
95. P. A. Ascierto, M. Kalos, D. A. Schaer, M. K. Callahan, and J. D. Wolchok, "Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types," Clinical Cancer Research, vol. 19, no. 5, pp. 1009-1020, 2013.